Organised in partnership with:

Advanced Therapies – Opportunities and Challenges

14th November, London


14 November 2017 – British Medical Association, London



Introduction by Conference Host, Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals


Opening Keynote Session:  “The Future of Advanced Therapies”

Key Topics:
– Vision for Advanced Therapies
– How are ATMP technologies advancing in Europe generally, and the UK specifically?

  • Keynote Speaker: Peter Goodfellow, Scientific Advisor, Abingworth
    • “Regenerating the Future, Again”
  • Lord James O’Shaughnessy, Parliamentary Under Secretary of State for Health (Lords), UK Government
    • tbc
  • Ian Campbell, Director for Health and Life Sciences, Innovate UK
    • “Innovate UK Supporting Research Development & Manufacturing in Advanced Therapies”
  • Christian K. Schneider, Director of National Institute for Biological Standards and Control (NIBSC)
    • “Advanced Therapies – regulatory challenges”
10:15 Coffee Break & Networking

Building Effective R&D Partnerships to Accelerate ATMPs

Key Topics:
– How have each of your organisations used partnerships to create effective R&D platforms
– What are you doing to accelerate the development ATMPs in partnership with other firms?
– What changes could Europe make to support effective R&D partnerships?

  • Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals
  • Eduardo Bravo, Chief Executive Officer, TiGenix; EBE President
  • Qasim Rafiq, Senior Lecturer (Associate Professor) in Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL
  • Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult
  • Richard Barker, Founding Director, Centre for the Advancement of Sustainable Medical Innovation (CASMI) (moderator)
12:00 Lunch & Networking

ATMPs as Cures – The Opportunities and Challenges for Europe

Key Topics:
– Emerging regenerative medicines will likely cure serious illness, but often these will be one-time treatments. How do we manage this paradigm shift in the EU to support R&D and better health?
– How are each of you focused on developing treatments, how does this R&D differ from traditional small molecule R&D?
– How can small biotech work with larger companies to foster the development of Regenerative Medicines and de-risk the inevitable disruption created highly effective, but one time treatment cures?

  • Michaël Hocquemiller, Scientific Director, Lysogene
    • “Pioneering gene therapies for CNS disorders”
  • Adrien Lemoine, VP Business Development & Operations, Orchard Therapeutics
    • “Overcoming the complex challenges associated with the development of ex vivo gene therapies for rare diseases”
  • Karen Hodgkin, Chief Operating Officer, Cell Medica
    • “Cell Medica: Novel approaches for the treatment of Solid Tumours”
  • James McBlane, CAT Alternate Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA)
    • “Partnering well together – creating a global ecosystem for advanced therapies”
  • Gabriele Proetzel, Director, Regenerative Medicine, Takeda (moderator)
14:30 Coffee Break & Networking

R&D and Commercialisation 2020 – Maximising the Value of European Innovation

Key Topics:
– What is the UK doing to foster and support both the ATMP (regenerative medicine) sector, and improve the landscape broadly for European innovation?
– How can the EU create value from ‘home grown’ ATMPs while they continue to seek international partnerships? Is manufacturing a key to keeping more of the value chain in the EU?
– How are each of your organisations addressing the changing EU environment for ATMPs? How specifically are you adapting to meet the needs of the coming 3 – 5 years in technology developments in regenerative medicines?

  • Magda Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI)
  • Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
  • Deborah Morrison, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE)
  • Steve Bates, Chief Executive Officer, BioIndustry Association (BIA)
  • Michael Stein, Chief Executive Officer and Chairman, Oxstem Ltd
  • Duane Schulthess, Managing Director, Vital Transformation (moderator)
16:30 Wrap-up followed by a networking cocktail

Supported by: